△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Concepts
NAD+ replenishment via NRPT supports healthy aging physiology
Primary
Elysium's Basis/NRPT mechanism is that nicotinamide riboside supplies a vitamin B3 precursor that raises NAD+ availability, while pterostilbene is paired with NR as part of the intervention. Because NAD+ is described as a core redox cofactor that declines with age and disease, maintaining NAD+ through biosynthetic intermediates is proposed to support aging-relevant cellular metabolism. Testable predictions include increased NAD+/vitamin B3 catabolome markers after supplementation and measurable changes in age-associated physiological endpoints.
The core premise is credible: nicotinamide riboside is a vitamin B3 precursor, NAD+ is a central redox cofactor, and the supplied evidence says NRPT raises urinary vitamin B3 catabolome markers after dosing. The weaker step is the jump from higher NAD+ metabolism markers to healthier aging physiology. That link is biologically plausible, but the evidence here does not show that restored NAD+ causally improves aging biology across tissues.
Supporting evidence: Nicotinamide riboside is described as a vitamin B3-derived biosynthetic intermediate that can raise NAD+ availability.; NAD+ is described as a core redox cofactor whose levels are thought to decline with age and disease.; In a 7-day open-label pilot trial, NRPT increased urinary methyl-nicotinamide and methylated pyridone carboxamides.
Counter evidence: The broad healthy-aging claim depends on a low-confidence assumption that findings from menopause symptoms, UVB mouse models, ALS contexts, and B-vitamin epigenetic aging studies generalize to aging physiology.; Urinary catabolites show altered vitamin B3 handling, but they do not by themselves prove improved tissue NAD+ function or durable physiological benefit.
Explanatory power4.0
The theory explains the biomarker result well: giving an NAD+ precursor should change vitamin B3 catabolites, and it did. It explains the menopause symptom findings less well because the trial was open-label, lasted 7 days, and measured self-reported symptoms. Placebo effects, regression to the mean, short-term symptom variability, and pterostilbene-specific effects remain live explanations. The UVB mouse data fit a protective biology claim, but they do not pin the effect specifically on NAD+ replenishment.
Supporting evidence: NRPT supplementation predicted increased NAD+/vitamin B3 catabolome markers, and the pilot trial observed increased urinary methyl-nicotinamide and methylated pyridone carboxamides.; Menopausal women reporting symptoms had reduced frequency and magnitude of bloating, hot flashes, and poor sleep after 7 days, with an increased E2/E1 ratio.; In mice, combined nicotinamide riboside and pterostilbene inhibited UVB-induced skin swelling more than either compound alone.
Counter evidence: The menopause study was open-label and short, so expectancy and natural symptom fluctuation are hard to exclude.; The ALS evidence is marked low confidence and mixes model data with a reported human pilot context.; The evidence does not isolate whether NR, pterostilbene, their combination, or nonspecific supplementation effects explain the physiological endpoints.
Falsifiability8.0
The theory makes testable claims. NRPT should raise NAD+/vitamin B3 catabolome markers, and it should produce measurable changes in aging-associated physiological endpoints. A blinded randomized trial could refute the useful version of the theory if NRPT raises catabolites without improving prespecified physiology, or if tissue NAD+ measures fail to move at all. The broad phrase healthy aging physiology is soft, but the biomarker and endpoint predictions are concrete enough to test.
Supporting evidence: The theory predicts increased NAD+/vitamin B3 catabolome markers after supplementation.; The theory predicts measurable changes in age-associated physiological endpoints.; The menopause pilot measured urinary vitamin B3 catabolites, symptoms, and E2/E1 ratio before and after NRPT.
Counter evidence: Healthy aging physiology is a broad endpoint unless trials name specific tissues, time windows, and clinical or functional thresholds.; If any favorable biomarker shift is treated as support, the theory becomes too easy to rescue after weak physiological results.
Reasoning tree
premise
NRPT is proposed to support healthy aging physiology by combining nicotinamide riboside as an NAD+ precursor with pterostilbene as part of the intervention.
medium confidence - 3 linked evidence items
premise
assumes
Nicotinamide riboside is a vitamin B3-derived biosynthetic intermediate that can raise NAD+ availability.
high confidence - 2 linked evidence items
prediction
predicts
NRPT supplementation should increase measurable NAD+/vitamin B3 catabolome markers.
high confidence - 2 linked evidence items
observation
observed_in
In a 7-day open-label pilot trial, NRPT significantly increased urinary methyl-nicotinamide and methylated pyridone carboxamides.
medium confidence - 1 linked evidence item
premise
assumes
NAD+ is a core redox cofactor whose levels are thought to decline with age and disease.
high confidence - 2 linked evidence items
derivation
implies
If NAD+ availability declines with age and disease, then maintaining NAD+ through biosynthetic intermediates may support aging-relevant cellular metabolism.
medium confidence - 1 linked evidence item
assumption
requires
Changes in NAD+ availability or NAD(H) catabolism are biologically meaningful indicators of how NAD+ precursors are used, recycled, and eliminated.
medium confidence - 1 linked evidence item
prediction
predicts
NRPT supplementation should produce measurable changes in age-associated physiological endpoints.
medium confidence - 3 linked evidence items
observation
observed_in
In menopausal women reporting symptoms, 7 days of NRPT was associated with reduced frequency and magnitude of bloating, hot flashes, and poor sleep, plus an increased E2/E1 ratio.
medium confidence - 1 linked evidence item
observation
observed_in
In mice, combined nicotinamide riboside and pterostilbene inhibited UVB-induced skin swelling more than either compound alone and protected against UVB-induced immune suppression.
medium confidence - 1 linked evidence item
observation
observed_in
In ALS models and a reported human pilot context, nicotinamide riboside with pterostilbene was associated with motor neuron protection or survival-related benefit.
low confidence - 1 linked evidence item
project_implication
implies
A funding or evidence-discovery project should prioritize studies measuring both NAD+/vitamin B3 catabolome markers and aging-associated physiological endpoints after NRPT supplementation.
medium confidence - 2 linked evidence items
premise
implies
B-vitamin status can be linked to biological aging measures, as homocysteine-lowering B-vitamin treatment was associated with normalization of accelerated epigenetic aging in mild cognitive impairment.
medium confidence - 1 linked evidence item
assumption
requires
Findings from vitamin B3/NAD+ metabolism, menopause symptoms, UVB injury models, ALS models, and B-vitamin epigenetic aging studies are relevant to a broader healthy-aging physiology claim.
low confidence - 5 linked evidence items
Public endorsements
mentions
Dan Alminana appears in public records as an Elysium leader and named inventor on an Elysium patent covering nicotinamide riboside chloride formulations, and in a public interview he discusses getting a larger trial funded. That links him publicly to the NR product program, but the provided evidence does not show him directly stating that NRPT-driven NAD+ replenishment supports healthy aging physiology.
The public evidence ties Eric Marcotulli to Elysium as founder and CEO and shows him discussing longevity in broad terms, plus one tweet about SIRT6 and diseases of aging. It does not show him publicly talking about NRPT, NAD+ replenishment, pterostilbene, Basis, or the specific mechanism in this theory.
silent
The dossier includes no quote or publication where Eric Marcotulli discusses NRPT, NAD+ replenishment, Basis, or the healthy-aging mechanism. The provided records are generic Elysium pages and company materials, not a public statement from him on this theory.
silent
The evidence ties Leonard Guarente to Elysium publicly as its founder/chief scientist, and it shows his general healthspan views, but none of the supplied quotes or records show him explicitly endorsing, describing, or disputing the specific NRPT and NAD+ replenishment mechanism in public.
mentions
Mark Morris is publicly tied to Elysium and named as an inventor on Elysium patents covering crystalline forms of nicotinamide riboside chloride, the NR part of the NRPT theory. That is a public connection to the mechanism. The record here does not show a direct statement from Morris endorsing the full claim that NRPT supports healthy aging physiology, and it shows no contradiction either.
NR, pterostilbene, and ibudilast may protect neurons by countering oxidative stress and neuroinflammation
The ALS mouse publication identifies oxidative stress and neuroinflammation as major contributors to ALS pathology. The causal theory is that combining nicotinamide riboside and pterostilbene with ibudilast protects motor neurons by acting on these stress and inflammatory pathways, which should slow neurodegeneration and extend survival in ALS models. Testable predictions include motor neuron preservation and longer survival in treated ALS mice compared with untreated controls.
The starting premises are credible. Oxidative stress and neuroinflammation are named as major ALS contributors, NR has a plausible NAD+ and redox link, pterostilbene has antioxidant and anti-inflammatory data, and ibudilast targets inflammatory pathways. The weak point is causal density: ALS is not explained by these two pathways alone, and the evidence given does not prove that this three-drug mix reaches the right cells, at the right dose, through the right mechanism.
Supporting evidence: The ALS mouse publication identifies oxidative stress and neuroinflammation as major contributors to ALS pathology.; NR can increase NAD+ availability, a redox-related metabolic pathway tied to cellular stress responses.; Pterostilbene reduced UVB-induced tissue swelling and immune suppression in mice, supporting anti-inflammatory activity outside ALS.; Ibudilast targets inflammatory pathways relevant to neuroinflammation.
Counter evidence: The theory assumes that reducing oxidative stress and neuroinflammation is sufficient to protect motor neurons in ALS models.; The menopause and UVB studies support parts of the biology, but they do not directly establish ALS motor neuron protection.
Explanatory power6.0
The theory explains the reported mouse outcome in a coherent way: treated ALS mice had motor neuron protection and longer survival, matching the proposed stress-and-inflammation mechanism. But the explanation is still underdetermined. A survival gain could come from general metabolic support, altered disease behavior, dosing artifacts, or model-specific effects. The evidence fits the theory, but it does not yet force the theory.
Biological age testing tracks modifiable aging rate through DNA methylation
Elysium's Index program is based on the theory that biological age and rate of aging can be measured from DNA methylation patterns using an epigenetic clock trained to predict PhenoAge. The causal intervention theory is indirect: if lifestyle, nutritional, demographic, or biochemical factors alter aging biology, then those changes should be detectable as changes in epigenetic age or rate of aging. Testable predictions include reproducible associations between risk factors or interventions and DNA methylation-derived aging measures.
The premise is credible: DNA methylation clocks can estimate PhenoAge-linked biological age, and Index appears built on that same target using principal components. The weaker step is biological meaning. A methylation score can track risk-associated molecular state without proving that it measures the causal speed of aging itself.
Supporting evidence: Index is described as a principal component-based epigenetic clock trained to predict PhenoAge and report epigenetic age and rate of aging.; Elevated plasma total homocysteine was associated with a higher epigenetic aging rate in older adults with mild cognitive impairment.; B-vitamin treatment reportedly normalized accelerated epigenetic aging in hyperhomocysteinemic individuals.
Counter evidence: The theory assumes methylation-derived aging measures reflect biologically meaningful aging processes rather than chronological age, cell-composition shifts, or assay artifacts.; The causal path from lifestyle or biochemical change to slower aging remains indirect.
Explanatory power5.0
The theory explains why homocysteine risk and homocysteine-lowering treatment might move an Index aging signal. That is useful, but it does not yet beat simpler explanations: methylation may be responding to inflammation, nutrition status, blood-cell composition, or regression toward baseline. The NAD-related evidence shows biochemical response to supplementation, but it does not directly show a DNA methylation aging change.
Homocysteine-lowering B vitamins may slow accelerated epigenetic aging
The Index-related Aging Cell study links elevated total homocysteine with faster epigenetic aging in older adults with mild cognitive impairment. The causal theory is that elevated homocysteine contributes to accelerated biological aging, and that lowering homocysteine with B vitamins can normalize this acceleration as measured by DNA methylation clocks including Index. Testable predictions include a positive association between homocysteine and rate of epigenetic aging, plus reduced epigenetic age acceleration after B-vitamin treatment.
The premise is biologically credible: total homocysteine is already tied to dementia risk, B vitamins can lower elevated homocysteine, and the VITACOG mild cognitive impairment cohort showed higher homocysteine alongside faster epigenetic aging. The weak point is causality. The theory needs homocysteine to be part of the driver chain, but the current evidence can still fit a marker model where homocysteine tracks nutrition, renal function, inflammation, or disease burden.
Supporting evidence: The Aging Cell study reports significant associations between plasma total homocysteine and rate of epigenetic aging across DNA methylation clock measures, including Index.; B-vitamin treatment is stated to lower elevated total homocysteine.; Index showed normalization of accelerated epigenetic aging in hyperhomocysteinemic individuals after B-vitamin treatment.
Counter evidence: The theory assumes DNA methylation clocks such as Index capture biologically meaningful aging-rate changes, not only biomarker movement.; The causal assumption is rated low confidence: confounding in an older mild cognitive impairment population has not been ruled out.
Explanatory power6.0
The theory explains two linked observations: high homocysteine tracks faster epigenetic aging, and lowering homocysteine with B vitamins tracks normalization on Index. That is a coherent chain. It does not yet beat simpler alternatives decisively. B vitamins could change methylation readouts through one-carbon metabolism without slowing biological aging itself, or high homocysteine could be a downstream signal of poorer baseline health.
NR plus pterostilbene protects against UVB-induced inflammatory and immune aging stressors
The UVB study proposes that nicotinamide riboside and pterostilbene can reduce harmful inflammatory and immune effects of ultraviolet radiation, including tissue swelling and immune suppression, which are linked to skin carcinogenesis. The causal theory is that systemic NR and pterostilbene improve resilience to environmental stress by dampening UVB-induced inflammation and preserving immune responsiveness. Testable predictions include lower post-UVB skin swelling and preserved contact hypersensitivity responses in treated animals versus controls.
The starting biology is credible: UVB can drive swelling and immune suppression, and the cited mouse study directly tests systemic nicotinamide riboside plus pterostilbene against those endpoints. The weak point is the aging claim. The evidence supports acute UVB inflammatory and immune stress protection in mice, while the bridge to immune aging and skin carcinogenesis remains partly inferential.
Supporting evidence: The 2024 UVB mouse study reports that environmental UVB radiation causes sunburn-like inflammatory effects and immune perturbations involved in skin carcinogenesis.; Combined nicotinamide riboside plus pterostilbene inhibited UVB-induced skin swelling more than either agent alone.; Pterostilbene alone and the combination inhibited UVB-induced immune suppression in both low-dose and high-dose contact hypersensitivity models.
Counter evidence: The key direct evidence comes from mouse ear swelling and contact hypersensitivity models, not human UVB exposure or longitudinal skin cancer outcomes.; The evidence context says menopause, NAD catabolism, homocysteine, and ALS publications provide only indirect background support for this UVB-specific theory.
Explanatory power6.0
NRPT may improve menopause-transition symptoms through NAD+-linked hormone metabolism
The menopause pilot trial states that NAD+ is needed for production of hormones such as estradiol, and that both NAD+ and estradiol decline with age. The causal theory is that NRPT supplementation raises NAD+-related metabolism and thereby shifts estrogen biology, reflected by an increased estradiol-to-estrone ratio, which should reduce menopause-transition symptoms such as hot flashes, bloating, and poor sleep. Testable predictions include increased vitamin B3/NAD+ catabolites, higher E2/E1 ratio, and symptom improvements after short-term NRPT dosing.
The starting biology is plausible but thin. NRPT contains nicotinamide riboside, an NAD+ precursor, and the pilot reports the expected rise in urinary vitamin B3 catabolites after 7 days. The estrogen link is weaker: NAD+ is relevant to hormone metabolism, and estradiol declines with age, but the theory still has to show that a short NRPT course changes estrogen biology enough to affect hot flashes, bloating, and sleep.
Supporting evidence: NRPT contains 250 mg nicotinamide riboside and 50 mg pterostilbene, given daily for 7 days.; The pilot reports significant increases in urinary methyl-nicotinamide and methylated pyridone carboxamides in all groups.; The menopause-symptom group showed a significant increase in urinary estradiol-to-estrone ratio after dosing.
Counter evidence: The causal bridge from NAD+ metabolism to symptom-relevant estrogen biology is asserted more than demonstrated.; Urinary E2/E1 ratio may be an imperfect proxy for the tissue-level estrogen changes that would drive symptoms.; Seven days is a short window for claiming biologically meaningful endocrine symptom change.
Explanatory power4.0
The theory fits the pilot observations, but it does not yet beat simpler explanations. The same group had higher vitamin B3 catabolites, a higher E2/E1 ratio, and fewer reported symptoms, which is the pattern the theory predicts. The problem is the study was open-label, had 40 total participants, and the symptom group knew they were taking the supplement. Placebo effects, regression to the mean, expectancy, and week-to-week symptom fluctuation are still very much alive.
Ryan Dellinger is publicly named as an inventor on Elysium patent filings for crystalline nicotinamide riboside chloride, the NR component tied to the company's NAD+ replenishment story. That is public involvement with the mechanism's ingredient platform, but the record here does not show a direct public statement from him endorsing the broader healthy aging theory or NRPT claims.
The dossier gives no public quote, publication, or attributed statement from Whitney Christopher on Elysium's NRPT and NAD+ theory. The only record is a patent involving nicotinamide riboside and urolithin, but it names different inventors and does not show Whitney Christopher endorsing, discussing, or disputing this theory.
Supporting evidence: The theory predicts greater motor neuron preservation in treated ALS mice than untreated controls.; The theory predicts longer survival in treated ALS mice than untreated controls.; The ALS mouse publication reportedly observed both motor neuron protection and extended survival after NR, pterostilbene, and ibudilast treatment.
Counter evidence: The evidence context does not separate the contribution of NR, pterostilbene, and ibudilast.; The context does not show pathway readouts proving that oxidative stress and neuroinflammation changed in the treated ALS tissue.; Alternative explanations remain open because the reported observation is outcome-level rather than mechanism-resolving.
Falsifiability8.0
This theory is clearly testable. It predicts motor neuron preservation and longer survival in treated ALS mice compared with untreated ALS controls. It could fail cleanly if treated mice do not survive longer, if motor neurons are not preserved, or if oxidative and inflammatory markers do not move in the expected direction. The best falsification test would include single-agent arms and pathway readouts, because the combination claim otherwise has too many escape routes.
Supporting evidence: The theory names concrete outcomes: motor neuron preservation and survival extension.; The predictions compare treated ALS mice with untreated ALS controls.; The mechanism implies measurable stress and inflammatory pathway changes.
Counter evidence: The theory does not specify effect sizes, dosing thresholds, timing, or required biomarker changes.; Without single-agent and pairwise comparison arms, failure or success of the combination is hard to assign to the proposed mechanism.
Reasoning tree
premise
Oxidative stress and neuroinflammation are major contributors to ALS pathology.
high confidence - 1 linked evidence item
premise
requires
Nicotinamide riboside can increase NAD+ availability, a redox-related metabolic pathway that may influence cellular stress responses.
medium confidence - 2 linked evidence items
premise
requires
Pterostilbene has antioxidant and anti-inflammatory protective effects in experimental stress models.
medium confidence - 2 linked evidence items
observation
observed_in
Nicotinamide riboside plus pterostilbene reduced UVB-induced tissue swelling and immune suppression in mice, supporting anti-inflammatory activity outside ALS.
medium confidence - 1 linked evidence item
premise
requires
Ibudilast targets inflammatory pathways relevant to neuroinflammation.
medium confidence - 1 linked evidence item
assumption
assumes
Interventions that reduce oxidative stress and neuroinflammation can protect motor neurons in ALS models.
medium confidence - 1 linked evidence item
derivation
implies
Combining nicotinamide riboside, pterostilbene, and ibudilast should counter both oxidative stress and inflammatory contributors to ALS pathology.
medium confidence - 3 linked evidence items
derivation
implies
Countering oxidative stress and neuroinflammation should slow motor neuron degeneration in ALS models.
medium confidence - 1 linked evidence item
prediction
predicts
Treated ALS mice should show greater motor neuron preservation than untreated ALS controls.
high confidence - 1 linked evidence item
observation
observed_in
Nicotinamide riboside, pterostilbene, and ibudilast were reported to protect motor neurons and extend survival in ALS mice.
high confidence - 1 linked evidence item
project_implication
implies
The combination therapy is a plausible candidate for ALS follow-up studies focused on oxidative stress, neuroinflammation, motor neuron preservation, and survival endpoints.
medium confidence - 1 linked evidence item
prediction
predicts
Treated ALS mice should survive longer than untreated ALS controls.
The provided record set does not show Dan Alminana publicly addressing this specific ALS theory. He appears in company materials and an NR-related patent, but nothing here ties him to a public statement endorsing, mentioning, or disputing the claim that NR, pterostilbene, and ibudilast protect neurons in ALS through oxidative stress and neuroinflammation.
Eric Marcotulli is publicly tied to Elysium Health and has spoken broadly about longevity technology, and he once shared interest in SIRT6 research tied to aging. None of the cited material shows him endorsing, discussing, or disputing the specific ALS theory that combines nicotinamide riboside, pterostilbene, and ibudilast to reduce oxidative stress and neuroinflammation.
The record set does not show any public statement from Eric Marcotulli about this ALS theory, or about nicotinamide riboside, pterostilbene, and ibudilast protecting neurons through oxidative stress and neuroinflammation. The supplied items are general Elysium pages and company background material, not a theory-specific endorsement, mention, or contradiction from him.
The provided evidence ties Leonard Guarente to Elysium Health and to general longevity and healthspan views, but it does not show him publicly discussing this specific ALS theory: combining nicotinamide riboside, pterostilbene, and ibudilast to reduce oxidative stress and neuroinflammation and protect motor neurons. On this theory, the dossier is silent.
The record shows Mark Morris as an Elysium Health leader and co-inventor on nicotinamide riboside chloride patents, but none of the supplied evidence ties him publicly to the specific ALS theory about NR, pterostilbene, and ibudilast reducing oxidative stress and neuroinflammation. On this dossier, he is publicly connected to NR, not to this combined neuroprotection claim.
The public evidence here ties Ryan Dellinger to Elysium patents on crystalline forms of nicotinamide riboside chloride. It does not show him publicly discussing the ALS theory, the NR plus pterostilbene plus ibudilast combination, oxidative stress, neuroinflammation, or motor neuron protection. On this record, he is publicly silent on that theory.
silent
The provided evidence does not show any public statement by Whitney Christopher about this ALS theory. The only record is a patent on nicotinamide riboside plus urolithin, and it does not mention Whitney Christopher, pterostilbene, ibudilast, ALS, oxidative stress, or neuroinflammation in a way that ties this person to the theory.
Supporting evidence: Risk factors for aging-related disease are predicted to associate with accelerated DNA methylation-derived aging measures.; Elevated homocysteine was significantly associated with higher epigenetic aging rate.; Homocysteine-lowering B vitamins reportedly normalized accelerated epigenetic aging detected by Index.
Counter evidence: Nicotinamide riboside plus pterostilbene changed vitamin B3 catabolites, but the supplied evidence does not say it improved Index, PhenoAge, or another methylation aging endpoint.; The menopause-transition pilot was open-label and short, 7 days, which leaves placebo effects and symptom fluctuation very much alive.; Mouse UVB protection supports stress-response biology, not direct measurement of human aging rate by methylation.
Falsifiability8.0
This theory is testable. It predicts that defined risk factors and interventions should produce reproducible, directionally consistent changes in DNA methylation-derived aging measures. A controlled trial could falsify the practical claim if a pathway with clear biochemical movement, such as homocysteine lowering, repeatedly fails to move Index or moves it opposite to prediction.
Supporting evidence: The theory predicts reproducible associations between aging risk factors and accelerated methylation-derived aging measures.; It also predicts that interventions affecting relevant biochemical pathways should produce measurable changes in epigenetic age or aging rate.; The homocysteine and B-vitamin claims provide a concrete test case with a measurable exposure, intervention, and methylation-clock endpoint.
Counter evidence: The theory needs prespecified effect sizes, timing, tissue source, and failure criteria. Without those, weak or null results can be explained away too easily.; Because the causal theory is indirect, a changed methylation score does not by itself prove changed aging biology.
Reasoning tree
premise
Biological age and rate of aging can be estimated from DNA methylation patterns using an epigenetic clock trained to predict PhenoAge.
high confidence - 1 linked evidence item
premise
requires
Index is a principal component-based epigenetic clock that, like DNAmPhenoAge, is trained to predict PhenoAge and can report epigenetic age and rate of aging.
high confidence - 1 linked evidence item
assumption
assumes
DNA methylation-derived aging measures reflect biologically meaningful aging processes rather than only chronological age or measurement artifacts.
medium confidence - 1 linked evidence item
assumption
assumes
Changes in lifestyle, nutritional, demographic, or biochemical factors can alter aging biology in ways detectable by epigenetic age or rate-of-aging measures.
medium confidence - 1 linked evidence item
derivation
implies
If a modifiable factor changes aging biology, then a valid DNA methylation clock should show a corresponding change in epigenetic age or rate of aging.
medium confidence - 1 linked evidence item
prediction
predicts
Risk factors for aging-related disease should be reproducibly associated with accelerated DNA methylation-derived aging measures.
high confidence - 1 linked evidence item
observation
observed_in
Elevated plasma total homocysteine was significantly associated with higher rate of epigenetic aging in older adults with mild cognitive impairment.
high confidence - 1 linked evidence item
derivation
implies
Evidence that modifiable biochemical factors such as homocysteine and NAD-related metabolism associate with or respond to interventions supports the plausibility that biological aging signals are modifiable and measurable.
medium confidence - 4 linked evidence items
project_implication
implies
Elysium's Index program can be used to track whether modifiable risk factors or interventions are associated with changes in biological age or rate of aging, but causal interpretation remains indirect unless intervention effects are reproducible and controlled.
medium confidence - 1 linked evidence item
prediction
predicts
Interventions that modify relevant biochemical pathways should produce measurable changes in DNA methylation-derived aging measures.
medium confidence - 1 linked evidence item
observation
observed_in
Treatment with homocysteine-lowering B vitamins normalized accelerated epigenetic aging detected by Index in hyperhomocysteinemic individuals.
high confidence - 1 linked evidence item
premise
implies
NAD+ levels are thought to decline with age and disease, and NAD+ precursor supplementation can alter the NAD(H) metabolome and catabolism profile.
medium confidence - 1 linked evidence item
observation
observed_in
Nicotinamide riboside plus pterostilbene supplementation significantly changed vitamin B3 catabolites and increased urinary methyl-nicotinamide and methylated pyridone carboxamides.
high confidence - 1 linked evidence item
observation
observed_in
Nicotinamide riboside plus pterostilbene reduced menopause-transition symptom frequency and severity and increased the estradiol-to-estrone ratio in an open-label pilot trial.
medium confidence - 1 linked evidence item
observation
observed_in
Nicotinamide riboside and pterostilbene protected against UVB-induced tissue swelling and immune suppression in mouse models.
The evidence here does not show Dan Alminana publicly discussing Elysium's DNA methylation and epigenetic clock theory. One record is an interview with him, but the provided excerpt covers mission, values, and trial funding, not biological age testing or methylation clocks. The other records link him to Elysium generally, or to a nicotinamide riboside patent, which is a different subject.
The provided evidence shows Eric Marcotulli as Elysium's CEO and includes general comments about longevity technology, founder advice, and SIRT6 research. None of the quotes or publication excerpts tie him directly to Elysium's specific theory that DNA methylation clocks and PhenoAge-based epigenetic measures track modifiable aging rate.
The provided public records show Elysium leadership and company pages that list Index as a product, but they do not contain any statement from Eric Marcotulli about DNA methylation, epigenetic clocks, PhenoAge, or whether biological age testing tracks modifiable aging rate. On this evidence, he is publicly silent on the theory.
The evidence shows Leonard Guarente is a founder and chief scientist of Elysium Health, but none of the provided quotes or company records show him publicly discussing, endorsing, or disputing the specific Index theory that DNA methylation testing tracks a modifiable aging rate.
The public records here show Mark Morris as an Elysium leader and inventor on nicotinamide riboside patents, but they do not show him discussing Index, DNA methylation clocks, PhenoAge, or biological age testing. On this evidence, he stays silent on the theory.
silent
Ryan Dellinger appears in the provided public record only as an inventor and assignor on Elysium patents about crystalline forms of nicotinamide riboside chloride. Those records do not mention DNA methylation, epigenetic clocks, PhenoAge, biological age testing, or whether such measures track modifiable aging rate. On this evidence, he is publicly silent on the theory.
silent
The record set does not show Whitney Christopher making any public statement about Elysium's DNA methylation and epigenetic clock theory. The only provided record is a patent on nicotinamide riboside and urolithin, and it does not mention Whitney Christopher or the biological age testing claim.
Supporting evidence: Higher total homocysteine was associated with increased rate of epigenetic aging in the VITACOG mild cognitive impairment population.; B-vitamin treatment was followed by normalization of accelerated epigenetic aging in hyperhomocysteinemic individuals on Index.; The proposed intervention directly targets the measured exposure, total homocysteine.
Counter evidence: The evidence context does not show that reduced epigenetic age acceleration led to better clinical aging outcomes.; Alternative explanations remain live: nutritional status, cognitive impairment severity, kidney function, inflammation, or methylation chemistry could explain part of the signal.
Falsifiability8.0
This theory is easy to put at risk. Measure total homocysteine and DNA methylation clocks before and after B-vitamin treatment, predefine Index or another clock as the endpoint, and test whether the homocysteine drop predicts reduced epigenetic age acceleration. A clean null result in hyperhomocysteinemic participants would hurt the theory badly. Good. The claim has handles.
Supporting evidence: The theory predicts that individuals with higher total homocysteine should show higher rates of epigenetic aging or greater epigenetic age acceleration.; It predicts that B-vitamin treatment in hyperhomocysteinemic individuals should reduce epigenetic age acceleration relative to baseline or untreated comparison groups.; The evidence context names a direct test: measure total homocysteine and DNA methylation clock outcomes before and after B-vitamin intervention, with Index as a primary or key secondary endpoint.
Counter evidence: The theory may become harder to falsify if any clock movement is accepted after the fact, so endpoints and clock hierarchy need to be specified in advance.; A methylation-clock change alone may not falsify or confirm true biological aging unless paired with clinical or functional outcomes.
Reasoning tree
premise
Elevated total homocysteine is proposed to contribute to accelerated biological aging as measured by DNA methylation clocks in older adults with mild cognitive impairment.
medium confidence - 1 linked evidence item
observation
observed_in
In the VITACOG mild cognitive impairment population, higher plasma total homocysteine was significantly associated with increased rate of epigenetic aging across DNA methylation clock measures, including Index.
high confidence - 1 linked evidence item
derivation
implies
If elevated homocysteine is linked to faster epigenetic aging, then hyperhomocysteinemia may be a modifiable risk factor for accelerated epigenetic aging.
medium confidence - 1 linked evidence item
premise
requires
B-vitamin treatment can lower elevated total homocysteine.
high confidence - 1 linked evidence item
observation
observed_in
Index showed normalization of accelerated epigenetic aging in hyperhomocysteinemic individuals after treatment with homocysteine-lowering B vitamins.
high confidence - 1 linked evidence item
derivation
implies
Lowering homocysteine with B vitamins may normalize homocysteine-associated acceleration of epigenetic aging.
medium confidence - 1 linked evidence item
assumption
assumes
DNA methylation clocks such as Index capture biologically meaningful changes in aging rate rather than only biomarker variation.
medium confidence - 1 linked evidence item
assumption
assumes
The association between homocysteine and epigenetic aging is at least partly causal and not fully explained by confounding factors in the mild cognitive impairment population.
low confidence - 1 linked evidence item
prediction
predicts
B-vitamin treatment in hyperhomocysteinemic individuals should reduce epigenetic age acceleration relative to baseline or untreated comparison groups.
medium confidence - 1 linked evidence item
project_implication
implies
A useful test of the theory would measure total homocysteine and DNA methylation clock outcomes before and after B-vitamin intervention, with Index included as a primary or key secondary epigenetic aging endpoint.
medium confidence - 1 linked evidence item
prediction
predicts
Individuals with higher total homocysteine should show higher rates of epigenetic aging or greater epigenetic age acceleration.
The provided public records tie Dan Alminana to Elysium Health, its mission, and patents around nicotinamide riboside, but they do not show him discussing homocysteine, B vitamins, or epigenetic aging clocks. On this evidence, he stays silent on the theory.
The provided public evidence ties Eric Marcotulli to Elysium Health and to broad longevity topics, but it does not show him endorsing, discussing, or disputing the specific claim that lowering homocysteine with B vitamins slows epigenetic aging.
No provided quote or publication ties Eric Marcotulli to this theory. The supplied records are general Elysium pages and leadership coverage, and none mention homocysteine, B vitamins, or slowing epigenetic aging.
The provided evidence links Leonard Guarente to Elysium Health and to broad healthspan goals, but it does not show him publicly discussing homocysteine, B-vitamin lowering, or epigenetic aging clocks. On this record, he stays silent on this specific theory.
The record ties Mark Morris to Elysium Health as a leadership-team member and inventor on nicotinamide riboside chloride patents. None of the provided evidence mentions homocysteine, B vitamins, DNA methylation clocks, or epigenetic aging, so there is no public endorsement, mention, or contradiction of this theory here.
Ryan Dellinger appears in the provided evidence only as an inventor/assignor on Elysium patents about crystalline nicotinamide riboside chloride. That is public involvement with an NAD-related product, but it does not mention homocysteine, B-vitamin lowering of homocysteine, mild cognitive impairment, or epigenetic aging clocks. On this record, there is no public endorsement, mention, or contradiction of the specific theory.
silent
The supplied public evidence does not show Whitney Christopher endorsing, mentioning, or disputing the homocysteine and B-vitamin theory. The only record is a patent on nicotinamide riboside and urolithin, which is a different intervention and does not address homocysteine, B vitamins, or epigenetic aging clocks.
The theory explains the observed mouse endpoints reasonably well: treated animals had less swelling and better preserved contact hypersensitivity after UVB. Still, the mechanism is broad. Reduced inflammation, altered UVB response, pterostilbene-specific effects, NAD-related metabolism, or general stress-response changes could all fit the same pattern. The combination result helps, but it does not pin down the causal chain.
Supporting evidence: The combination outperformed either agent alone for UVB-induced skin swelling, which fits the claim that NR plus pterostilbene gives stronger protection against at least some UVB stress endpoints.; Preserved contact hypersensitivity responses in treated UVB-exposed mice fit the prediction that the intervention protects immune responsiveness.; Human studies show NR plus pterostilbene can alter vitamin B3 and NAD-related catabolites, making systemic biological activity plausible.
Counter evidence: Pterostilbene alone inhibited UVB-induced immune suppression in both low-dose and high-dose models, so the combination is not clearly required for the immune endpoint.; NR alone worked better in the low-dose UVB model than the high-dose model, which weakens a simple general-resilience explanation.; The evidence does not show that NAD metabolism caused the UVB protection rather than traveling alongside it.
Falsifiability8.0
This is a testable theory. It predicts lower post-UVB swelling, preserved contact hypersensitivity, and some advantage for the combination over single agents. Those claims can fail cleanly in dose-response studies, replication cohorts, blinded animal experiments, and eventually controlled human UVB-challenge studies.
Supporting evidence: One prediction is lower post-UVB skin or ear swelling in treated animals versus untreated controls.; A second prediction is stronger preserved contact hypersensitivity responses in treated UVB-exposed animals.; A third prediction is that the combination should outperform either compound alone for at least some inflammatory or immune endpoints.
Counter evidence: The broader phrase 'improve resilience to environmental stress' is looser than the UVB-specific endpoints and would need narrower operational definitions.; The link to skin carcinogenesis would require longer studies with tumor-related endpoints, not just acute swelling or contact hypersensitivity.
Reasoning tree
premise
Systemic nicotinamide riboside plus pterostilbene can protect against harmful inflammatory and immune effects caused by UVB radiation.
high confidence - 1 linked evidence item
premise
assumes
Environmental UVB radiation can cause tissue swelling and immune perturbations that are involved in skin carcinogenesis.
high confidence - 1 linked evidence item
observation
observed_in
In mice, combined nicotinamide riboside and pterostilbene inhibited UVB-induced skin swelling more than either agent alone.
high confidence - 1 linked evidence item
derivation
implies
Combining nicotinamide riboside with pterostilbene may provide broader or stronger protection against UVB-induced inflammatory and immune stress than nicotinamide riboside alone.
medium confidence - 1 linked evidence item
prediction
predicts
The combination of nicotinamide riboside and pterostilbene should outperform either compound alone for at least some UVB-induced inflammatory or immune endpoints.
medium confidence - 1 linked evidence item
observation
observed_in
Pterostilbene alone and nicotinamide riboside plus pterostilbene inhibited UVB-induced immune suppression in both low-dose and high-dose UVB contact hypersensitivity models.
high confidence - 1 linked evidence item
observation
observed_in
Nicotinamide riboside alone inhibited UVB-induced immune suppression more effectively in the low-dose UVB model than in the high-dose UVB model.
medium confidence - 1 linked evidence item
derivation
implies
Nicotinamide riboside plus pterostilbene may improve resilience to environmental stress by dampening UVB-induced inflammation and preserving immune responsiveness.
medium confidence - 1 linked evidence item
assumption
requires
Mouse UVB-induced ear swelling and contact hypersensitivity models are relevant proxies for inflammatory and immune-aging stressors in skin.
medium confidence - 1 linked evidence item
assumption
requires
Protection against acute UVB-induced swelling and immune suppression is relevant to reducing biological processes linked to skin carcinogenesis.
medium confidence - 1 linked evidence item
premise
assumes
Nicotinamide riboside supplementation is used to raise or maintain NAD-related metabolism, which is thought to decline with age and disease.
medium confidence - 1 linked evidence item
premise
observed_in
Nicotinamide riboside plus pterostilbene supplementation can measurably alter vitamin B3 and NAD-related catabolites in humans.
medium confidence - 2 linked evidence items
prediction
predicts
Treated animals exposed to UVB should show lower post-UVB skin or ear swelling than untreated controls.
high confidence - 1 linked evidence item
prediction
predicts
Treated animals exposed to UVB should preserve stronger contact hypersensitivity responses than untreated UVB-exposed controls.
high confidence - 1 linked evidence item
project_implication
implies
The NR plus pterostilbene intervention is a plausible candidate for further testing as a systemic strategy to reduce UVB-related inflammatory and immune stress in skin.
medium confidence - 1 linked evidence item
assumption
assumes
The available menopause, NAD catabolism, homocysteine, and ALS publications provide only indirect background support and do not directly test UVB-induced skin inflammation or immune suppression.
The provided evidence ties Dan Alminana to Elysium Health as an employee and inventor on an NR-related patent, and the Nasdaq interview shows he speaks publicly about the company’s mission and trials. None of the supplied material shows him publicly discussing the specific theory that nicotinamide riboside plus pterostilbene protects against UVB-induced inflammatory or immune aging stressors.
The provided evidence links Eric Marcotulli to Elysium Health and shows him discussing longevity technology in general, plus one older tweet about SIRT6. None of the quotes or company records mention nicotinamide riboside, pterostilbene, UVB, skin inflammation, immune suppression, or the specific claim that this combination protects against UVB-induced stressors. On this dossier, he stays silent on the theory.
The provided evidence does not contain any statement from Eric Marcotulli, or a clearly attributable leadership statement, about the specific theory that nicotinamide riboside plus pterostilbene protects against UVB-induced inflammatory or immune aging stressors. The records are generic company and leadership pages, not theory-specific endorsements or contradictions.
The dossier ties Leonard Guarente to Elysium Health as founder/co-founder and chief scientist, but none of the provided public quotes or publications show him discussing the specific claim that nicotinamide riboside plus pterostilbene protects against UVB-induced inflammatory or immune aging stressors. On this theory, the public record here is silent.
The public record here ties Mark Morris to Elysium and to patents on nicotinamide riboside chloride, but nothing provided mentions the specific UVB theory, pterostilbene, skin inflammation, immune suppression, or protection against UVB-induced aging stressors. On this evidence, he stays silent on the theory.
silent
The only public evidence here is Ryan Dellinger listed as an inventor on Elysium patents about crystalline nicotinamide riboside chloride. That connects him to NR formulation work, but it does not publicly state or imply support for the specific theory that NR plus pterostilbene protects against UVB-induced inflammatory or immune-aging stressors. There is no quote, publication, or direct statement from him on that claim.
silent
The record provided does not show Whitney Christopher publicly endorsing, mentioning, or contradicting this UVB theory. The only evidence is a patent about nicotinamide riboside with urolithin, credited to other inventors, and it does not address pterostilbene, UVB-induced inflammation, or immune suppression.
Supporting evidence: In symptomatic women, NRPT was followed by lower reported frequency and magnitude of bloating, hot flashes, and poor sleep.; The symptom changes occurred alongside a significant increase in urinary E2/E1 ratio.; Women without menopause-transition symptoms did not show significant symptom endpoint changes.
Counter evidence: The trial was open-label and had no placebo control.; The causal assumption that symptom improvements came from NAD+-linked estrogen metabolism has low confidence in the supplied evidence graph.; The observed symptom changes could reflect placebo effects, regression to the mean, or uncontrolled short-term variation.
Falsifiability8.0
This is the strongest Popperian feature. The theory makes concrete predictions: NRPT should increase vitamin B3 or NAD+ catabolites, raise E2/E1 ratio in symptomatic women, and reduce symptom frequency or severity. A randomized placebo-controlled trial could break the theory cleanly if NAD+ catabolites rise but E2/E1 and symptoms do not move, or if symptoms improve without the predicted hormone shift.
Supporting evidence: The theory predicts increased vitamin B3 or NAD+ catabolites after short-term NRPT dosing.; The theory predicts an increased estradiol-to-estrone ratio in women with menopause-transition symptoms.; The theory predicts reduced frequency or severity of symptoms such as hot flashes, bloating, and poor sleep.
Counter evidence: The current pilot mainly compares post-treatment values with baseline, so it does not yet supply the controlled test needed to reject placebo-based explanations.; The theory could become harder to falsify if any symptom improvement is accepted without requiring the NAD+ and E2/E1 changes to move together.
Reasoning tree
premise
NRPT may improve menopause-transition symptoms through NAD+-linked changes in estrogen hormone metabolism.
medium confidence - 1 linked evidence item
premise
assumes
NAD+ is needed for production of key hormones such as estradiol.
medium confidence - 1 linked evidence item
derivation
implies
If NRPT increases NAD+-related metabolism, it may alter hormone metabolism related to estradiol production or clearance.
medium confidence - 2 linked evidence items
derivation
implies
A shift in estrogen biology can be reflected by an increased urinary estradiol-to-estrone ratio.
medium confidence - 1 linked evidence item
derivation
implies
Improved estrogen biology could reduce menopause-transition symptoms such as hot flashes, bloating, and poor sleep.
medium confidence - 1 linked evidence item
prediction
predicts
Short-term NRPT dosing should reduce the frequency or severity of menopause-transition symptoms.
medium confidence - 1 linked evidence item
observation
observed_in
In the menopause-symptom group, NRPT significantly decreased the frequency and magnitude of bloating, hot flashes, and poor sleep after 7 days.
high confidence - 1 linked evidence item
assumption
assumes
The observed symptom improvements are causally related to NRPT-induced NAD+-linked estrogen metabolism rather than placebo effects, regression to the mean, or other uncontrolled factors.
low confidence - 1 linked evidence item
project_implication
requires
A stronger test of the theory would require a controlled trial measuring NAD+ metabolism, E2/E1 ratio, and menopause symptoms together.
high confidence - 2 linked evidence items
observation
observed_in
Women without menopause-transition symptoms did not report significant changes in symptom endpoints after NRPT dosing.
medium confidence - 1 linked evidence item
prediction
predicts
Short-term NRPT dosing should increase the estradiol-to-estrone ratio in women with menopause-transition symptoms.
medium confidence - 1 linked evidence item
observation
observed_in
In the menopause-symptom group, NRPT significantly increased the urinary estradiol-to-estrone ratio after 7 days.
high confidence - 1 linked evidence item
assumption
assumes
Urinary estradiol-to-estrone ratio is a valid proxy for the relevant estrogen-biology changes driving menopause-transition symptoms.
medium confidence - 1 linked evidence item
premise
assumes
Both NAD+ and estradiol levels decline with age.
medium confidence - 2 linked evidence items
premise
assumes
Reduced estradiol levels are associated with undesirable symptoms of the menopause transition.
medium confidence - 1 linked evidence item
premise
requires
NRPT contains nicotinamide riboside, an NAD+ precursor, plus pterostilbene.
high confidence - 3 linked evidence items
premise
implies
Prior clinical trials have shown that oral NRPT supplementation significantly increases NAD+ levels.
medium confidence - 1 linked evidence item
prediction
predicts
Short-term NRPT dosing should increase vitamin B3 or NAD+ catabolites.
high confidence - 2 linked evidence items
observation
observed_in
In a 7-day open-label pilot trial, NRPT significantly increased urinary methyl-nicotinamide and methylated pyridone carboxamides in all groups.
high confidence - 1 linked evidence item
assumption
assumes
Seven days of NRPT exposure is sufficient to produce biologically meaningful changes in NAD+ metabolism and estrogen-related symptom biology.
The provided public records tie Dan Alminana to Elysium as a cofounder/employee and inventor on an NR-related patent, but they do not show him publicly discussing the specific menopause theory here: NRPT affecting menopause-transition symptoms through NAD+-linked hormone metabolism, estradiol biology, or an estradiol-to-estrone ratio shift. On this evidence, he stays silent on that claim.
The provided evidence shows Eric Marcotulli discussing Elysium Health, longevity technology, founder advice, and SIRT6 research, but nothing here addresses NRPT, menopause-transition symptoms, estradiol or estrone, or an NAD+-linked hormone mechanism. On this dossier, he stays silent on the specific theory.
There is no quoted statement from Eric Marcotulli here, and the supplied records do not show him discussing NRPT, NAD+, estradiol, menopause symptoms, or this mechanism. With this evidence, silence is the defensible call.
The provided public evidence ties Leonard Guarente to Elysium Health as founder/co-founder and chief scientist, but none of the quoted material has him discussing NRPT, menopause-transition symptoms, estradiol or estrone, or an NAD+-linked hormone-metabolism mechanism. On this record, he is publicly silent on this specific theory.
The public material here ties Mark Morris to Elysium as a leadership-team member and co-inventor on nicotinamide riboside chloride patents. It does not show him publicly discussing the specific theory that NRPT improves menopause-transition symptoms through NAD+-linked hormone metabolism, the estradiol-to-estrone ratio, or symptom relief.
Ryan Dellinger appears in the evidence only as an inventor and assignor on Elysium patents covering crystalline nicotinamide riboside chloride. That shows involvement with the compound, but it does not show a public statement from him about the menopause theory, NAD+-linked hormone metabolism, estradiol biology, or symptom relief. On this record, he stays silent on the specific theory.
silent
The provided evidence does not show any public statement, authorship, or attributed claim from Whitney Christopher about the menopause-related NRPT theory. The only record is a patent on nicotinamide riboside and urolithin assigned to Amazentis, and it names different inventors. That is not evidence that Whitney Christopher endorsed, mentioned, or contradicted this specific theory.
